40% of IBD patients are non-responsive to mainstay therapy

Inflammatory bowel disease (IBD) is characterized by chronic inflammation that is a result of an abnormal immune response mediated by cytokine storm and immune cell infiltration. While the precise cause of IBD remains elusive, it can be attributed to abnormal immune function, genetic factors, or exposure to environmental triggers such as pathogens. Prioritizing disease models that reflect the patient’s condition is paramount to better understand the pathophysiology of gut inflammation and develop effective treatments.

Patient-derived organoid-based platforms for IBD research

Organoid technology enables the development of patient-derived models of inflammation, incorporating the cellular diversity observed in vivo, including the various intestinal cell types, stromal elements, and immune cell components of the epithelium, within a 2D or 3D drug screening format.

PDO Monolayer

A ready-to-use translational screen designed for assessing epithelial barrier function, inflammation, and toxicity.

Our PDO Monolayer is an advanced and rapid solution that enables the proliferation and maturation of stem cells from intestinal crypts sourced from patient biopsies into a fully differentiated human epithelium. This process closely mimics the natural composition of in vivo gut epithelium, encompassing various types of intestinal cells. What sets our PDO Monolayer apart is its unique ability to be generated from a diverse biobank of IBD patients, making it the sole in vitro model that accurately represents the characteristics of the patient population.

Utilize our PDO Monolayer to model inflammation response, toxicity, and barrier function, providing you with the confidence you need to advance your lead candidates effectively.

discover more

PDO Co-culture systems

Emulate epithelial microenvironment with our fibroblast, bacteria PDO co-culture systems

The development of successful therapies requires evaluating a drug’s impact on multiple cell or tissue types. Modeling these intricate interactions often compromises scalability, posing a challenge for preclinical drug development. We offer unique organoid co-cultures to facilitate the development of candidates targeting inflammatory fibroblasts and immune cells within the gut epithelial microenvironment. Additionally, we can model host-microbiome interactions to screen for preventive therapies in IBD.

talk to sales

Want to know more?


Modelling inflammation “in a dish”

watch now


Patient-derived organoids as a relevant tool for preclinical IBD research and drug development

download now


Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal Barrier Function

view publication


Have any questions?

contact us